ALFRY: AI 评分 49/100 — AI 分析 (4月 2026)

Alfresa Holdings Corporation operates in the healthcare sector, focusing on pharmaceutical distribution, manufacturing, and medical-related services. The company serves hospitals, clinics, pharmacies, and drug stores across Japan and internationally.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Alfresa Holdings Corporation, a Japanese healthcare conglomerate, manufactures, wholesales, and distributes pharmaceuticals, diagnostic reagents, and medical devices. With a focus on ethical pharmaceuticals and self-medication products, the company serves hospitals, clinics, and pharmacies in Japan and internationally, maintaining a stable position in the medical distribution landscape.

ALFRY是做什么的？

Incorporated in 2003 and based in Tokyo, Japan, Alfresa Holdings Corporation has established itself as a key player in the healthcare sector. The company operates through its subsidiaries, engaging in the manufacture, wholesale, marketing, and import/export of a diverse range of healthcare products. These include pharmaceuticals, diagnostic reagents, and medical devices/equipment. Alfresa's operations are segmented into ethical pharmaceuticals wholesaling, self-medication products wholesaling, and manufacturing. The ethical pharmaceuticals division supplies hospitals, clinics, and dispensing pharmacies with essential products. The self-medication division caters to drug stores and pharmacies, offering over-the-counter drugs, health foods, and supplements. Alfresa also manufactures active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, providing contract manufacturing services. The company's medical-related business encompasses dispensing pharmacies and other healthcare activities, further solidifying its presence in the healthcare value chain. Alfresa's international reach extends its market presence beyond Japan, contributing to its revenue streams and overall growth.

ALFRY的投资论点是什么？

Alfresa Holdings Corporation presents a stable investment profile within the healthcare distribution sector. The company's diversified revenue streams, spanning ethical pharmaceuticals, self-medication products, and manufacturing, provide resilience against market fluctuations. With a P/E ratio of 12.91 and a dividend yield of 2.76% as of 2026-03-16, Alfresa offers a blend of value and income potential. The company's low beta of -0.16 suggests a lower sensitivity to market volatility compared to its peers. Growth catalysts include expanding its self-medication product lines and penetrating new international markets. Potential risks include regulatory changes in the pharmaceutical industry and increased competition from other distributors.

ALFRY在哪个行业运营？

Alfresa Holdings Corporation operates within the medical distribution industry, a sector characterized by steady growth driven by aging populations and increasing healthcare expenditure. The industry is competitive, with players like CHSYF, DMPHF, HAWPF, HTSUF, and MAHLY vying for market share. Trends include consolidation among distributors and increased focus on supply chain efficiency. Alfresa's diversified product portfolio and established distribution network position it favorably within this landscape.

Medical - Distribution

Healthcare

ALFRY有哪些增长机遇？

Expanding Self-Medication Product Lines: Alfresa can capitalize on the growing demand for over-the-counter drugs and health supplements. The global self-medication market is projected to reach $200 billion by 2028. By introducing innovative products and expanding its distribution network, Alfresa can increase its market share in this segment. Timeline: Ongoing.
Penetrating New International Markets: Alfresa has the opportunity to expand its presence in emerging markets with growing healthcare needs. The Asia-Pacific region, in particular, offers significant growth potential. By establishing partnerships and adapting its product offerings to local market demands, Alfresa can diversify its revenue streams. Timeline: 2-3 years.
Enhancing Contract Manufacturing Services: Alfresa can leverage its manufacturing capabilities to offer contract manufacturing services to other pharmaceutical companies. The global pharmaceutical contract manufacturing market is expected to reach $150 billion by 2027. By investing in advanced manufacturing technologies and expanding its capacity, Alfresa can attract new clients and generate additional revenue. Timeline: Ongoing.
Strengthening Digital Distribution Channels: Alfresa can enhance its online presence and develop digital distribution channels to reach a wider customer base. The e-pharmacy market is experiencing rapid growth, driven by increasing internet penetration and changing consumer preferences. By investing in e-commerce platforms and digital marketing strategies, Alfresa can capture a share of this growing market. Timeline: 1-2 years.
Developing Value-Added Services: Alfresa can differentiate itself from competitors by offering value-added services to its customers, such as inventory management, supply chain optimization, and data analytics. These services can help hospitals, clinics, and pharmacies improve their operational efficiency and reduce costs. By providing customized solutions and building strong customer relationships, Alfresa can enhance customer loyalty and generate recurring revenue. Timeline: Ongoing.

Market capitalization of $2.91 billion indicates a substantial presence in the healthcare sector.
P/E ratio of 12.91 suggests a reasonable valuation compared to earnings.
Dividend yield of 2.76% provides a steady income stream for investors.
Gross margin of 7.1% reflects the company's ability to manage its cost of goods sold.
Profit margin of 1.1% indicates areas for potential improvement in operational efficiency.

ALFRY提供哪些产品和服务？

Wholesales ethical pharmaceuticals to hospitals, clinics, and dispensing pharmacies.
Distributes self-medication products, including OTC drugs and health supplements, to drug stores and pharmacies.
Manufactures active pharmaceutical ingredients and pharmaceuticals.
Produces diagnostic reagents and medical devices.
Offers contract manufacturing services for pharmaceuticals.
Operates dispensing pharmacies.

ALFRY如何赚钱？

Revenue from wholesale distribution of pharmaceuticals and medical products.
Income from manufacturing and sales of active pharmaceutical ingredients and finished drugs.
Fees from contract manufacturing services.
Revenue generated from operation of dispensing pharmacies.

Hospitals and clinics.
Dispensing pharmacies.
Drug stores.
Other pharmaceutical companies (for contract manufacturing).

Established distribution network in Japan.
Diversified product portfolio spanning pharmaceuticals, diagnostics, and medical devices.
Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
Strong relationships with hospitals, clinics, and pharmacies.

什么因素可能推动ALFRY股价上涨？

Ongoing: Expansion of self-medication product lines to meet growing consumer demand for OTC drugs and health supplements.
Ongoing: Strategic partnerships to enhance distribution network and market reach in key regions.
Upcoming: Potential regulatory approvals for new pharmaceutical products, expanding the company's product portfolio.
Ongoing: Investment in digital distribution channels to capitalize on the growth of e-pharmacy market.
Ongoing: Development of value-added services to enhance customer loyalty and generate recurring revenue.

ALFRY的主要风险是什么？

Potential: Increased competition from other pharmaceutical distributors, leading to pricing pressures.
Potential: Changes in government regulations and healthcare policies, affecting reimbursement rates and market access.
Potential: Economic downturns affecting healthcare spending and consumer demand for pharmaceuticals.
Ongoing: Currency fluctuations between the U.S. dollar and the Japanese yen, impacting the value of the ADR.
Potential: Product liability claims or recalls, damaging the company's reputation and financial performance.

ALFRY的核心优势是什么？

Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.
Established distribution network in Japan.
Strong relationships with key customers, including hospitals and pharmacies.
Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.

ALFRY的劣势是什么？

Relatively low profit margin compared to industry peers.
Dependence on the Japanese market.
Exposure to regulatory changes in the pharmaceutical industry.
Limited international presence compared to global competitors.

ALFRY有哪些机遇？

Expanding self-medication product lines to capitalize on growing consumer demand.
Penetrating new international markets, particularly in Asia-Pacific.
Enhancing contract manufacturing services to generate additional revenue.
Strengthening digital distribution channels to reach a wider customer base.

ALFRY面临哪些威胁？

Increased competition from other pharmaceutical distributors.
Pricing pressures from generic drugs.
Changes in government regulations and healthcare policies.
Economic downturns affecting healthcare spending.

ALFRY的竞争对手是谁？

China Shineway Pharmaceutical Group Limited — Focuses on traditional Chinese medicine. — (CHSYF)
DMP Holdings Berhad — Operates primarily in Malaysia. — (DMPHF)
Haw Par Corporation Limited — Diversified conglomerate with healthcare interests. — (HAWPF)
Haisco Pharmaceutical Group Co Ltd — Specializes in innovative drugs. — (HTSUF)
Medipal Holdings Corporation — Another major pharmaceutical wholesaler in Japan. — (MAHLY)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Ryuji Arakawa
Headquarters: Tokyo, JP
Employees: 12,517
Founded: 2018

AI Insight

AI analysis pending for ALFRY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: ALFR

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Alfresa Holdings Corporation do?

Alfresa Holdings Corporation is a comprehensive healthcare company involved in the manufacture, wholesale, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Operating primarily in Japan and internationally, Alfresa serves a diverse customer base, including hospitals, clinics, dispensing pharmacies, and drug stores. The company's business model encompasses ethical pharmaceuticals wholesaling, self-medication products wholesaling, manufacturing of active pharmaceutical ingredients, and operation of dispensing pharmacies, positioning it as a key player in the healthcare supply chain.

What do analysts say about ALFRY stock?

Analyst consensus on ALFRY is currently unavailable due to limited coverage. Key valuation metrics include a P/E ratio of 12.91 and a dividend yield of 2.76% as of 2026-03-16. Growth considerations center around the company's ability to expand its product portfolio, penetrate new markets, and enhance its operational efficiency. Investors should conduct their own thorough research and consider their individual risk tolerance before making any investment decisions.

What are the main risks for ALFRY?

Alfresa Holdings Corporation faces several risks inherent to the healthcare distribution industry. These include increased competition from other pharmaceutical distributors, pricing pressures from generic drugs, and changes in government regulations and healthcare policies. Additionally, the company is exposed to currency fluctuations between the U.S. dollar and the Japanese yen, as well as potential product liability claims or recalls. Investors should carefully consider these risks before investing in ALFRY.